Advanced

Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

Hjorth-Hansen, H.; Stentoft, J.; Richter, J.; Koskenvesa, P.; Höglund, M.; Dreimane, A.; Porkka, K.; Gedde-Dahl, T.; Gjertsen, B. T. and Gruber, F. X., et al. (2016) In Leukemia 30(9). p.1853-1860
Abstract

Dasatinib (DAS) and interferon-α have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-α2b (PegIFN) after 3 months (M3). The starting dose of PegIFN was 15 μg/week and it increased to 25 μg/week at M6 until M15. The combination was well tolerated with manageable toxicity. Of the patients, 84% remained on PegIFN at M12 and 91% (DAS) and 73% (PegIFN) of assigned dose was given. Only one patient had a pleural effusion during first year, and three more during the second year. After introduction of PegIFN we observed a steep increase in response rates. Major... (More)

Dasatinib (DAS) and interferon-α have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-α2b (PegIFN) after 3 months (M3). The starting dose of PegIFN was 15 μg/week and it increased to 25 μg/week at M6 until M15. The combination was well tolerated with manageable toxicity. Of the patients, 84% remained on PegIFN at M12 and 91% (DAS) and 73% (PegIFN) of assigned dose was given. Only one patient had a pleural effusion during first year, and three more during the second year. After introduction of PegIFN we observed a steep increase in response rates. Major molecular response was achieved in 10%, 57%, 84% and 89% of patients at M3, M6, M12 and M18, respectively. At M12, MR 4 was achieved by 46% and MR 4.5 by 27% of patients. No patients progressed to advanced phase. In conclusion, the combination treatment appeared safe with very promising efficacy. A randomized comparison of DAS±PegIFN is warranted.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
publishing date
type
Contribution to journal
publication status
published
subject
in
Leukemia
volume
30
issue
9
pages
8 pages
publisher
Nature Publishing Group
external identifiers
  • scopus:84973163267
ISSN
0887-6924
DOI
10.1038/leu.2016.121
language
English
LU publication?
no
id
77b98ce0-2c14-41e0-be66-d2ebfc478747
date added to LUP
2016-12-20 07:26:40
date last changed
2017-10-01 05:27:53
@article{77b98ce0-2c14-41e0-be66-d2ebfc478747,
  abstract     = {<p>Dasatinib (DAS) and interferon-α have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-α2b (PegIFN) after 3 months (M3). The starting dose of PegIFN was 15 μg/week and it increased to 25 μg/week at M6 until M15. The combination was well tolerated with manageable toxicity. Of the patients, 84% remained on PegIFN at M12 and 91% (DAS) and 73% (PegIFN) of assigned dose was given. Only one patient had a pleural effusion during first year, and three more during the second year. After introduction of PegIFN we observed a steep increase in response rates. Major molecular response was achieved in 10%, 57%, 84% and 89% of patients at M3, M6, M12 and M18, respectively. At M12, MR 4 was achieved by 46% and MR 4.5 by 27% of patients. No patients progressed to advanced phase. In conclusion, the combination treatment appeared safe with very promising efficacy. A randomized comparison of DAS±PegIFN is warranted.</p>},
  author       = {Hjorth-Hansen, H. and Stentoft, J. and Richter, J. and Koskenvesa, P. and Höglund, M. and Dreimane, A. and Porkka, K. and Gedde-Dahl, T. and Gjertsen, B. T. and Gruber, F. X. and Stenke, L. and Eriksson, K. M. and Markevärn, B. and Lübking, A. and Vestergaard, H. and Udby, L. and Bjerrum, O. W. and Persson, I. and Mustjoki, S. and Olsson-Strömberg, U.},
  issn         = {0887-6924},
  language     = {eng},
  month        = {09},
  number       = {9},
  pages        = {1853--1860},
  publisher    = {Nature Publishing Group},
  series       = {Leukemia},
  title        = {Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients},
  url          = {http://dx.doi.org/10.1038/leu.2016.121},
  volume       = {30},
  year         = {2016},
}